Factor Bioscience To Unveil Imacrophages Engineered To Combat Solid Tumors At The ISSCR Annual Meeting

2025-06-10 07:46:13

(MENAFN- PR Newswire) "We are excited to present the latest data from our engineered iMacrophage program, as well as recent advances in our gene editing and cell differentiation platforms at ISSCR 2025," said Dr. Matt Angel, Co-Founder, Chairman and CEO of Factor. "The data we will be showcasing this week include the first demonstration of targeted delivery of IL-12, a potent immunomodulatory cytokine with established anti-tumor activity, to the solid tumor microenvironment using engineered macrophages. These results represent a major milestone in our work to develop new therapies to treat cancer."

"The data include targeted delivery of IL-12 to solid tumors using engineered macrophages."

Post thi

Dr. Kyle Garland, Factor's Director of Translational Science, added, "After spending more than a decade laying the groundwork by developing cutting-edge RNA-based cell-engineering technologies, Factor is now leveraging these innovative platforms to develop next-generation therapies for patients in need. We are excited to share these remarkable advances in Hong Kong over the next few days."

Details of the presentations are below:

"Hypoimmune iPSC-derived Macrophages Engineered to Express IL-12 Activate Lymphocytes Against Platinum-Resistant Ovarian Cancer." -to be presented by Ian Hay on June 13 from 4:00-5:00 pm HKST, Organ Generation and Regeneration (OGR) and Clinical Applications (CA) Session 3: (Poster Presentation #F1249), Exhibit & Poster Hall (3BCDE, Level 3).

"UltraSliceTM mRNA Incorporating 5-Methoxyuridine Efficiently Inserts Transgene Sequences in iPSCs with High Viability and Mitigates dsRNA Production." -to be presented by Cassandra Ng on June 12 from 5:00-6:00 pm HKST, Disease Modeling and Drug Discovery (DMDD) Continued, Pluripotency and Development (PD) Session 2: (Poster Presentation #T1348), Exhibit & Poster Hall (3BCDE, Level 3).

"Directed Differentiation of mRNA-Reprogrammed iPSCs via Bioreactors Generates Clinically Relevant Yields of Neural Stem and Progenitor Cells that can be Engineered to Secrete Therapeutic Proteins." -to be presented by Claire Aibel on June 13 from 5:00-6:00 pm HKST, Organ Generation and Regeneration (OGR) and Clinical Applications (CA) Session 3: (Poster Presentation #F1228), Exhibit & Poster Hall (3BCDE, Level 3).

For more information about the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, visit .

About FACT-112
FACT-112 is an mRNA-reprogrammed macrophage engineered using Factor's patented UltraSliceTM gene editing platform to deliver IL-12 to solid tumors. Factor is developing FACT-112 for the treatment of platinum-resistant ovarian cancer and other malignant neoplasms.

About Factor Bioscience
Founded in 2011, Factor Bioscience is a biotechnology company focused on using its patented gene-editing platform to develop life-saving cell and gene therapies. Factor Bioscience is privately held and headquartered in Cambridge, MA. For more information, visit .

SOURCE Factor Bioscience Inc.

MENAFN10062025003732001241ID1109655624

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.